Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jun 30, 2023	Dec 31, 2022	Jun 30, 2022
Net Income	-35.07	-17.43	18.69	-24.54	-33.28	-33.28
Depreciation & Amortization	-	-	-	-	2.78	2.78
Stock-Based Compensation	3.92	0.83	0.6	3.35	4.4	4.4
Other Adjustments	6.26	5.96	-29.85	-	-0.47	-0.47
Change in Receivables	0.36	-1.98	-	-	-2.62	-
Changes in Accounts Payable	0.15	2.24	-2.25	-	-4.21	-
Changes in Accrued Expenses	-1.95	1.05	-1.18	-	-4.01	-
Changes in Unearned Revenue	-	-	-	-	-20.19	-
Changes in Other Operating Activities	-0.12	-1.5	0.27	-	-2.35	-
Operating Cash Flow	-22.59	-10.84	-13.7	-53.82	-59.93	-59.93
Capital Expenditures	-	-	-	-	-1.04	-1.04
Purchases of Investments	-	-	-	-	-48.4	-48.4
Proceeds from Sale of Investments	-	-	-	-	28.2	28.2
Investing Cash Flow	-	-	-	-	-21.24	-21.24
Long-Term Debt Issued	6	18.43	-	-	-	-
Net Long-Term Debt Issued (Repaid)	6	18.43	-	-	-	-
Issuance of Common Stock	0.66	-	-	-	7.21	7.12
Net Common Stock Issued (Repurchased)	0.66	-	-	-	7.21	7.12
Other Financing Activities	-3.81	68.66	5	-	-	-
Financing Cash Flow	74.17	87.09	5	19.8	7.21	7.21
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.66	0	-	-	-5.18	-5.18
Net Cash Flow	54.25	76.25	-8.7	-21.24	-79.13	-79.13
Free Cash Flow	-22.59	-10.84	-13.7	-53.82	-60.97	-60.97
Free Cash Flow Per Share	-0.01	-4.87	-7.64	-20.84	-10.66	-10.66
Levered Free Cash Flow	-28.29	2.78	14.77	-24.54	-62.28	-31.54
Unlevered Free Cash Flow	-30.65	-12.31	-15.02	-58.65	-98.38	-67.64

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q